Recent FDA review process of inconclusive clinical studies creates a potentially unhealthy decision-making environment for patients needing gadolinium-enhanced MRIs.
Orest Boyko, MD, PhD
Advertisement
Articles by Orest Boyko, MD, PhD
Advertisement
Latest Updated Articles
U.S. Patients Left Fending For Themselves with Gadolinium Safety RisksPublished: December 11th 2017 | Updated:
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Molecular Imaging in Focus: Emerging Insights on the PET and SPECT Imaging Agent 61Cu-NU101 for PCa
2
The Inflection Point for AI in Radiology: Emerging Insights for 2026
3
Mammography Study Assesses Ability of AI to Predict DCIS Recurrence After Breast Surgery
4
SPECT/CT Agent Garners FDA Fast Track Designation for Inflammation Assessment in Interstitial Lung Disease
5